ABSTRACT-Many of the disorders in urinary, biochemical, and hematological parameters induced by salt-loading in stroke-prone spontaneously hypertensive rats (SHRSP) were significantly ameliorated by chronic treatment with angiotensin converting enzyme inhibitors, imidapril (1 and 2 mg/kg) and enalapril (2 mg/kg). Through the improvement of these parameters, the treatment reduced the incidence of stroke but did not suppress the development of hypertension. These results suggest that the prophylaxis of stroke in SHRSP is probably due to systemic improvement as judged from the parameters of renal functions.
Some angiotensin converting enzyme (ACE) inhibitors, enalapril (1), captopril (2) , delapril (3) , and cilazapril (4), have been reported to exert a preventive effect on stroke in stroke-prone spotaneously hypertensive rats (SHRSP). The mechanism, however, is unclear.
Imidapril, a new ACE inhibitor, and enalapril equally lower blood pressure in spontaneously hypertensive rats (SHR) at more than 2 mg/kg, p.o. and in two kidney one clip renal hypertensive rats at more than 0.5 mg/kg, p.o. (5) . In SHRSP maintained on a 1 o-NaCl drinking solu tion, which is an accelerator of stroke incidence (6, 7) , the preventive effect on stroke was not equipotent between the two agents. Imidapril at 0.5 mg/kg/day and enalapril at 2 mg/kg/day equally protected SHRSP from stroke occurrence to a certain extent, while imidapril at 2 mg/kg/day and enalapril at 5 mg/kg/day completely prevented stroke, although neither agent suppressed hypertension development (8) .
Among the many antihypertensive agents, only some f blockers are reported to reduce levels of blood urea nitro gen (BUN), creatinine (CRNN), phospholipid (PL) and triglyceride (TG) in SHRSP (9) (10) (11) , while the effects of ACE inhibitors on these parameters in SHRSP have not yet been investigated.
In the present experiments, we examined: 1) the influ ence of salt-loading on various biochemical parameters in SHRSP and Wistar Kyoto (WKY) rats and 2) the effect of imidapril and enalapril on these parameters in salt-loaded SHRSP to investigate the mechanism of stroke prophy laxis. Thirty-nine male SHRSP (obtained from Prof. Okamoto of Kinki University and bred at Tanabe Seiyaku Co., Ltd.) and 16 male WKY rats (Charles River Japan, Inc.) were maintained on a normal diet from 4 to 11 weeks of age, followed by a special diet (with high NaCI and low protein content; Funabashi-SP, Funabashi Farm Co., Ltd.) from 11 to 16 weeks of age. At 11 weeks of age, the SHRSP were divided into 2 groups based upon the systolic blood pressure as measured by the tail cuff method (BP monitor, MK-1000, Muromachi Kikai Co., Ltd.) and body weight. One group (n = 8) was maintained on tap water ad libitum, as the non salt-loaded control. The other rats were given 1 01o NaCI solution instead of drinking water and subdivided into the 4 groups: control (n=7), imidapril (1, 2 mg/kg), and enalapril (2 mg/kg) (n = 8 each). WKY rats were also divided into 2 groups (n = 8 each) and served as the non-salt-loaded and salt loaded groups. Imidapril hydrochloride and enalapril maleate (both synthesized at Tanabe Seiyaku Co., Ltd.) were dissolved in distilled water and given orally to the rats once a day for 5 weeks from 11 weeks of age. Systolic blood pressure was measured 24 hr after the 4th-week dos ing. Neurological signs were observed daily (6). Body NAG: N-acetyl-fl-D-glucosaminidase. Salt-loaded rats were maintained on 1 % NaCI solution and a special diet (Funabashi SP), and non-salt-loaded rats were maintained on tap water and the special diet from 11 to 16 weeks of age. They were given the drugs orally once a day. After the final dosing, urine was collected for 24 hr. GOT: glutamic-oxaloacetic transaminase, GPT: glutamic pyruvic transaminase, LDH: lactic dehydrogenase, CPK: creatine phosphokinase, K: potassium, BUN: blood urea nitrogen, CRNN: creatinine, TC: total chlesterol, TG: triglycerides, PL: phospholipids, HDLC: high density lipoprotein cholesterol. Salt-loaded rats were maintained on 1% NaCl solution and a special diet (Funabashi SP) and non-salt-loaded rats were maintained on tapwater and the special diet from 11 to 16 weeks of age. They were given the drugs orally once a day. Statistical analyses were performed by Student's or Cochran's t-test for comparisons between the salt-loaded and non-salt-loaded groups, and Scheffe's multiple com parison test was used for assessing differences among the salt-loaded SHRSP. P <0.05 was considered to indicate a significant difference. One rat in the imidapril (2 mg/kg) administered group never drank the drinking fluid in the sanitary cage even in the repeated trials; We omitted the rat from the experiment.
SHRSP with or without salt-loading equally developed severe hypertension; their systolic blood pressure was 201.2 ± 3.3 mmHg at 11 weeks of age (n = 39). Blood pres sure in the SHRSP treated with the ACE inhibitors was equal to or higher than that in the salt-loaded control group. Imidapril and enalapril increased the body weight, which was low in the control group, to the level in the non-salt-loaded group (Table 1) . The blood pressure and body weight of WKY rats were not affected by salt-load ing (data not shown).
In the salt-loaded control group, one animal died spon taneously, and 3 showed signs of stroke during the treat ment period. One rat in the enalapril group also showed signs of stroke. The other rats survived without any evi dence of stroke.
In SHRSP, water intake, urine volume, urinary Na+, Cl-, Ca 21, protein excretion, and NAG activity were in creased by salt-loading (Table 1) . MCV and Ret were in creased, while RBC, Hb, Ht, and PLT were decreased (Table 2 ). These changes were suppressed by imidapril in a dose-dependent manner. The extent of the changes by 2 mg/kg of enalapril was nearly equal to that by 1 mg/kg of imidapril (Tables 1 and 2 ). Urinary occult blood was found microscopically in the salt-loaded control SHRSP, but not in the SHRSP given ACE inhibitors (data not shown). The transaminase activity ratio (GOT/GPT) and the CPK, CRNN, TC, TG, PL, and HDLC levels were in creased, while the GPT, K+, and HDLC/TC levels were decreased in SHRSP by salt-loading. All of these changes in salt-loaded SHRSP were ameliorated by both ACE inhi bitors equipotently (Table 3) .
The values in the salt-loaded and non-salt-loaded WKY were 38.1--t5.3 and 25.8 ± 0.9 ml/day in fluid intake, 29.4 ± 5.4 and 20.8 ± 1.1 ml/day in urine volume, 5.69±0.90 and 0.97±0.43 mEq/day in urinary Na+, 5.89±0.89 and 1.05±0.45 mEq/day in urinary Cl-, 0.078 ± 0.01 and 0.042 ± 0.005 mEq/day in urinary Cat+, and 11.2± 0.4 and 13.5-L0.7 mg/dl in BUN, respectively. The values of urinary Na+, Cl-, Ca t+, and BUN in salt loaded WKY were significantly different from those in non-salt-loaded ones. The other parameters were not affected significantly by salt-loading.
Some f-blockers are reported to reduce levels of BUN, CRNN, TG, and PL in SHRSP due to the reduction of oxygen consumption based on the fl-blockade (9-11).
Our results indicated that SHRSP are sensitive and WKY rats are resistant to salt-loading and that ACE inhi bitors improve the disorders of biochemical parameters in salt-loaded SHRSP as,6-blockers do.
In the salt-loaded SHRSP used here, imidapril and enalapril did not suppress the hypertension development. SHRSP is a low-renin type of hypertension model by na ture. Salt-loading brings volume loading and additionally suppresses renin release from the kidney. Under these cir cumstances, the dose of 2 mg/kg is too low for imidapril and enalapril to exert an antihypertensive effect.
Some investigators have suggested that proteinuria was prominent in salt-loaded SHRSP (1, 3, 7) . Reductions of proteinuria and urinary NAG activity in the SHRSP treat ed with ACE inhibitors may have resulted from the im provement of renal dysfunction as shown in this study. The changes of urinary parameters by salt-loading in WKY rats should be a result of their physiological responses. The remarkable increases in urine output and urinary Na+ and Cl excretion in SHRSP might have resulted from abnormal tubular reabsorption, because the changes were very markedly higher than those in WKY rats.
In the salt-loaded control SHRSP, the increases in BUN and CRNN and the hypokalemia suggested renal dysfunction. The decreases in RBC, Hb, and Ht and the increases in MCV and Ret probably resulted from kidney related anemia upon loss of erythropoietin, because it is biosynthesized in the kidney and promotes synthesis of red blood cells in the marrow. Imidapril prevented the deterioration of all these parameters suggestive of kid ney dysfunction. Stier et al. (1) reported that enalapril prevented proteinuria, improved the glomerular filtration rate, and reduced stroke in salt-loaded SHRSP. They also suggested a relationship between the amelioration of renal dysfunction and the prophylaxis of stroke. Our results support their suggestion on the basis of the biochemical parameters.
In salt-loaded SHRSP, the following changes were reported to occur in this order: 1) suppression of plasma renin activity, 2) histopathological disorders in renovas culature and elevation of urinary protein excretion, 3) elevation of plasma renin, and symptoms of stroke and histopathological disorders in cerebrovasculature (7) . The amelioration of renal dysfunction could be a key to pre vent stroke occurrence. A histopathological study was per formed in the rats that survived in this study. All of the salt-loaded control SHRSP showed fibrinoid necrosis, glomerular sclerosis, and tubular degeneration in the kid neys, and half of them had small hemorrhagic foci in the brains. Even with salt-loading, a few renal changes and no cerebrovascular disorders were observed in the group given imidapril at 1 mg/kg. Imidapril at 2 mg/kg/day showed an excellent prophylactic effect on both the renal and cerebrovascular disorders. The data suggested that renal disorder predated cerebrovascular hemorrhage (12) .
Reduction in PLT is reported to be a cause of addi tional cerebrovascular hemorrhage in SHRSP (13) . The PLT count was perfectly recovered by imidapril. The cerebrovascular endothelium might remain intact in SHRSP treated with ACE inhibitors, since it is reported that the damage of the vascular lumen enhances a fall in the PLT count (14) .
Cardiac abnormalities and elevated blood lipid levels were reported to be ingredients of the profile of stroke proneness (15) . The transaminase ratio, the levels of LDH and CPK, and blood lipid levels were decreased by both ACE inhibitors, and they seemed to protect the rats from heart disease. Moreover, the HDLC/TC ratio (an index of atherosclerosis) was also improved. This might be relat ed to an increase in the PGI2 level that was augmented via the kinin-kallikrein-prostaglandin system by imidapril, be cause the compound is a vascular protective factor.
In conclusion, improvement of biochemical param eters, especially reno-functional parameters, by ACE inhi bitors appears to relate to the preventive effect on stroke in salt-loaded SHRSP.
